RecruitingPhase 4NCT06637332

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

DAPTO-SNAP: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

Sponsor

Todd C. Lee MD MPH FIDSA

Enrollment

300 participants

Start Date

Nov 14, 2024

Study Type

INTERVENTIONAL

Conditions

Staphylococcus Aureus Bacteremia Staphylococcus Aureus Endocarditis Staphylococcus Aureus Septicemia S. Aureus Bacteremia S. Aureus Bloodstream Infection

Summary

This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Daptomycin for Injection and a drug called Vancomycin (IV) for people with s. aureus bacteremia, s. aureus bloodstream infection, and other related conditions. The study is currently recruiting participants at 16 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDaptomycin for Injection

Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg

DRUGVancomycin (IV)

Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care

Locations(18)

Blacktown Hospital

Blacktown, New South Wales, Australia

Concord Repatriation and General Hospital

Concord, New South Wales, Australia

John Hunter Hospital

Newcastle, New South Wales, Australia

Westmead Hospital

Westmead, New South Wales, Australia

Royal Brisbane and Women's Hospital

Herston, Queensland, Australia

Flinders Medical Centre

Bedford Park, South Australia, Australia

Box Hill Hospital

Box Hill, Victoria, Australia

Monash Medical Campus (Monash Medical Centre + Jesse McPherson Private Hospital)

Clayton, Victoria, Australia

Royal Melbourne Hospital

Parkville, Victoria, Australia

Fiona Stanley Hospital

Murdoch, Western Australia, Australia

Royal Perth Hospital

Perth, Western Australia, Australia

University of Alberta Hospital

Edmonton, Alberta, Canada

Fraser Health Authority (Surrey Memorial Hospital)

Surrey, British Columbia, Canada

Newfoundland Health Services (Health Sciences Centre and St. Clare's Mercy Hospital)

St. John's, Newfoundland and Labrador, Canada

Hamilton Health Sciences (Hamilton General Hospital and Juravinski Hospital)

Hamilton, Ontario, Canada

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Jewish General Hospital

Montreal, Quebec, Canada

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06637332

Related Trials

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

NCT048862846 locations

Staphylococcus Aureus Network Adaptive Platform Trial

NCT05137119161 locations

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

NCT066505011 location

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

NCT066504881 location

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus

NCT072536881 location